Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cytarabine + Etoposide + Mitoxantrone + Prexasertib |
| Synonyms | |
| Therapy Description |
Prexasertib (LY2606368) inhibits checkpoint kinase 1 (Chk1), which may result in accumulation of DNA damage and decreased tumor growth (PMID: 26141948, PMID: 28270495). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). | |
| Etoposide | Vepesid | EPEG|Eposin|VP-16|VP-16-213 | TOPO2 inhibitor 5 | Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
| Mitoxantrone | Novantrone | CL 232315 | TOPO2 inhibitor 5 | Novantrone (mitoxantrone) binds to and inhibits topoisomerase II, leading to DNA double strand breaks and decreased DNA repair (NCI Drug Dictionary). |
| Prexasertib | LY2606368|IC-83|ACR-368|ACR368|ACR 368 | CHK1 Inhibitor 18 | Prexasertib (LY2606368) inhibits checkpoint kinase 1 (Chk1), which may result in accumulation of DNA damage and decreased tumor growth (PMID: 26141948, PMID: 28270495, PMID: 32539469, PMID: 32510664). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03735446 | Phase I | Cytarabine + Etoposide + Mitoxantrone + Prexasertib | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | Terminated | USA | 0 |
CKB BOOST